================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
----------
FORM 8-K
----------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (date of earliest event reported) - May 9, 2003
----------
US Oncology, Inc.
(Exact Name of Registrant as Specified in Its Charter)
----------
DELAWARE 0-26190 84-1213501
(State or other jurisdiction of Commission file number (I.R.S. Employer Identification No.)
incorporation or organization)
16825 Northchase Drive, Suite 1300
Houston, Texas 77060
(Address of principal executive offices including zip code)
(832) 601-8766
(Registrant's telephone number, including area code)
================================================================================
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
99.1 Press release dated May 9, 2003 by US Oncology, Inc. (furnished and
not filed herewith solely pursuant to Item 12)
ITEM 9. Regulation FD Disclosure (the following discussion is furnished under
"Item 12. Results of Operations and Financial Conditions")
In accordance with SEC Release No. 33-8216, the following information,
required to be furnished under "Item 12. Results of Operations and Financial
Condition," is furnished under "Item 9. Regulation FD Disclosure."
On May 9, 2003, US Oncology, Inc. ("US Oncology") announced via press
release US Oncology's results for its first quarter ended March 31, 2003. A copy
of the press release is attached hereto as exhibit 99.1.
The information in this report and the attached exhibit are provided under
Item 12 of Form 8-K and are furnished to the Securities and Exchange Commission
("SEC"), but shall be not deemed "filed" with the SEC for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or of Sections 11 and 12(a)(2) of the Securities Act
of 1933, as amended. The furnishing of the information in this report and the
attached exhibit shall not be deemed an admission that such furnishing is
required by Regulation FD or that the information in this report and the
attached exhibit contains material information that is not otherwise publicly
available. The information in this report and the attached exhibit shall not be
incorporated by reference into any filing of US Oncology, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.
For additional risks about US Oncology's business, see its Annual Report on
Form 10-K for the year ended December 31, 2002, including disclosures under the
captions "Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," which are filed with the Securities and
Exchange Commission and are available on the SEC's website at www.sec.gov.
EXHIBIT INDEX
Exhibit
Number Title
- ------- -----
99.1 Press release dated May 9, 2003 by US Oncology, Inc.
================================================================================
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
US Oncology, Inc.
By: /s/ Bruce D. Broussard
--------------------------------
Bruce D. Broussard.
Chief Financial Officer
Date: May 9, 2003